TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Methodology

GLP-1 Pricing Verification Methodology

The whole rubric, in public, with the arithmetic. If you disagree with a score, you should be able to point at the exact category and the exact missing evidence.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

A price on this site is the lowest monthly figure a program prints on its own page for the stated plan, read on a stated date, with every required fee added and an annual membership spread over twelve months. Figures we could not re-read keep their original date and are marked as older records.

Answer last reviewed:
How the 100 points are allocatedMethodology v4.1
Pricing transparency20 ptsTotal annual cost20 ptsClinical oversight15 ptsPharmacy transparency15 ptsSupport10 ptsRegulatory disclosure10 ptsAccessibility10 pts
Show this figure as a table
Methodology v4.1 weights
CategoryPoints
Pricing transparency20 pts
Total annual cost20 pts
Clinical oversight15 pts
Pharmacy transparency15 pts
Support10 pts
Regulatory disclosure10 pts
Accessibility10 pts
Seven weighted categories, 100 points. NexLife scores 94; other programs are listed alphabetically while their v4.1 re-scores are pending. Read the methodology

Rules that override any score

  • No provider may purchase points, placement, or a review.
  • Missing evidence scores lower than evidence we checked ourselves. Absence is never scored as neutral.
  • Provider-reported evidence is labelled as provider-reported wherever it appears.
  • Prices are never compared across different program types. Starter, ongoing, maintenance, dose-tier, prepaid and month-to-month are scored separately.
  • Microdose programs are never scored against standard-dose programs.
  • Oral, sublingual and ODT compounded products are separated from injectables and carry an explicit evidence-limitation label.
  • Category weights and the arithmetic are published here; category breakdowns are added to provider pages as re-scores are completed.
  • Rankings are recomputed when material evidence changes, not on a marketing calendar.
How a price becomes a verified figure
1Locate the published priceThe provider's own page or checkout, never an aggregator.2Capture with a timestampScreenshot or archive stored against an evidence ID.3Itemise every required feeMembership, shipping, consultation, labs, dose surcharge.4Classify the programStarter, ongoing, maintenance, prepaid or month-to-month.5Normalise to monthly equivalentOur arithmetic, applied identically to every provider.6Second-reviewer checkA different person re-opens the source and confirms the figure.7Set a next-review dateThe figure is marked outdated when that date passes.
Show this figure as a table
Data table
StepStageWhat happens
1Locate the published priceThe provider's own page or checkout, never an aggregator.
2Capture with a timestampScreenshot or archive stored against an evidence ID.
3Itemise every required feeMembership, shipping, consultation, labs, dose surcharge.
4Classify the programStarter, ongoing, maintenance, prepaid or month-to-month.
5Normalise to monthly equivalentOur arithmetic, applied identically to every provider.
6Second-reviewer checkA different person re-opens the source and confirms the figure.
7Set a next-review dateThe figure is marked outdated when that date passes.
A figure that has not cleared step six is labelled provider-reported, not verified.
Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.
Third-party claims: how far published prices diverge for one providerSurvey captured 2026-07-24
Henry Meds (third-party claim)Lowest claim $179Highest claim $549Hims & Hers (third-party claimLowest claim $299Highest claim $549Mochi Health (third-party claiLowest claim $229Highest claim $308Ro (third-party claim)Lowest claim $199Highest claim $349Lowest claimHighest claim
Show this figure as a table
Data table
ItemLowest claimHighest claim
Henry Meds (third-party claim)$179$549
Hims & Hers (third-party claim)$299$549
Mochi Health (third-party claim)$229$308
Ro (third-party claim)$199$349
These are not prices. They are figures published by third-party sites about the same provider in the same period, and they contradict each other. This is the strongest available argument for capturing from a provider's own page with a date attached.
Every claim in the survey, with its sourceNot verified prices
Every claim in the survey, with its source
Provider and stated basisFigure publishedWhere it was published
Henry Meds — from$199/monthpeptidesexplorer.com (third-party claim)
Henry Meds — introductory month$297/monthtrimrx.com (third-party claim)
Henry Meds — flat monthly$449/monthformblends.com (third-party claim)
Henry Meds — maintenance dose, upper end$549/monthtrimrx.com (third-party claim)
Hims & Hers — introductory$299/monthtrimrx.com (third-party claim)
Hims & Hers — maintenance dose, upper end$549/monthtrimrx.com (third-party claim)
Recorded so a reader can check the spread themselves. We have not confirmed any of these figures with the provider, and we do not repeat them as prices anywhere on this site.

How a category is scored

Two of the seven v4.1 categories rest directly on price evidence, and together they carry 40 of the 100 points.

  • Pricing transparency (20 points) asks whether you can see what you will pay before you hand over any details. That means every dose and plan priced on the provider's own page, the required fees listed, and the terms stated: month to month, prepaid or sale. A price that only appears after intake or at checkout scores lower than one shown openly.
  • Total annual cost (20 points) asks what twelve months cost at a maintenance dose, with every required fee included.

A price counts only after seven steps. We locate it on the seller's own page, capture it with a timestamp, itemise every fee, classify the program type, convert to a monthly equivalent, have a second reviewer re-open the source, and set a next-review date. A figure that has not passed the second-reviewer check is labelled provider-reported, not verified.

Worked example, read November 6, 2026: NexLife charges $129 month to month, or $125, $119 and $115 a month on 3-, 6- and 12-month plans. That is $1,380 for 12 months, at the same price at every dose, with no membership fee.

How prices are normalised before comparison

The arithmetic, with figures from the price records:

Listed asRecorded asMonthly equivalent
$129 a month, month to month (NexLife)Month to month$129
$1,380 for 12 months (NexLife)Prepaid, 12 months$115
$114 a month, six months paid up front (Mondae)Prepaid, 6 months$114, compared only with prepaid terms
$89 sale price (WellMedr)Sale, with its end date if stated$89 while the sale runs
Any $199 annual membershipRequired feeAdds $16.58

Two rules sit on top. First, when the price changes with the dose, each tier is recorded, and annual cost uses the maintenance tier. Second, brand prices are counted per fill under their own conditions. Lilly's $449 Zepbound KwikPen price needs each refill within 45 days and is capped at 11 fills a calendar year, so we never multiply it by twelve. Brand and compounded figures are never ranked against each other.

What disqualifies a provider from ranking

These problems stop a price from being used in a ranking or a comparison:

  • It came from a third party. Since COR-008, figures from other review sites are labelled third-party claims. They are never ranked, summed or compared, however many sites repeat them. COR-009 explains why agreement between sites is not confirmation.
  • It has no term, dose or date. A number without these cannot be classified, so it is not used.
  • It has expired. A figure past its next-review date is marked outdated. Of the 28 records in the October 15, 2026 index, five are older records and carry their own dates.
  • It cannot be confirmed. A price a provider sends us privately stays labelled provider-reported until we can read it on the provider's own page.
  • It was offered for payment. No provider can pay to have a price shown, hidden or reworded.

Changes to this rubric

Prices change more often than the rubric, so the rules for handling them are versioned and dated too.

  • Re-reads. The full price index was last re-read on October 15, 2026. Twenty-three of 33 programs were read on the sellers' pages that day. NexLife's prices were read on November 6, 2026. When a re-read changes a figure, the new figure is dated and the old one stays in the records.
  • Rule changes. A change to how prices are classified or converted is applied to every record, not only to new ones. All monthly equivalents and annual costs are then recomputed.
  • Logged precedents. COR-008 created the third-party claim label. COR-009 withdrew a figure four sites agreed on. COR-010 replaced a third-party brand price with Lilly's own.

Every rule change is dated in the methodology and dataset changelog. Corrections to published figures are on the corrections log.

  • no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
Cite this pageCC BY 4.0

Tirzepatide Ranked. “GLP-1 Pricing Verification Methodology.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/pricing-verification-methodology/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.

Comparing 0 of 4